Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
University of Wisconsin, Madison
50 participants
Nov 19, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
radioactive substance called a "tracer" injected into the arm
positron emission tomography (PET) takes pictures of inside of the body
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06940427